[go: up one dir, main page]

CL2008003537A1 - 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain. - Google Patents

2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.

Info

Publication number
CL2008003537A1
CL2008003537A1 CL2008003537A CL2008003537A CL2008003537A1 CL 2008003537 A1 CL2008003537 A1 CL 2008003537A1 CL 2008003537 A CL2008003537 A CL 2008003537A CL 2008003537 A CL2008003537 A CL 2008003537A CL 2008003537 A1 CL2008003537 A1 CL 2008003537A1
Authority
CL
Chile
Prior art keywords
compound
aminopyrimidine
allergic
pain
treatment
Prior art date
Application number
CL2008003537A
Other languages
Spanish (es)
Inventor
Gonzalez Elena Carceller
Fuentes Eva Maria Medina
Via Josep Marti
Bernardo Marina Virgili
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of CL2008003537A1 publication Critical patent/CL2008003537A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alérgica, inmunológica o inflamatoria o dolor.2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immune, or inflammatory disease or pain.

CL2008003537A 2007-11-30 2008-11-27 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain. CL2008003537A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07381074 2007-11-30

Publications (1)

Publication Number Publication Date
CL2008003537A1 true CL2008003537A1 (en) 2009-03-06

Family

ID=39197144

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003537A CL2008003537A1 (en) 2007-11-30 2008-11-27 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.

Country Status (5)

Country Link
AR (1) AR069480A1 (en)
CL (1) CL2008003537A1 (en)
PE (1) PE20091035A1 (en)
TW (1) TW200936570A (en)
WO (1) WO2009068512A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2007752T1 (en) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
CN101511190A (en) 2006-07-11 2009-08-19 詹森药业有限公司 Pressure sensor fault detection
CL2008000467A1 (en) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA
WO2009038673A2 (en) 2007-09-14 2009-03-26 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
PE20110061A1 (en) 2008-06-12 2011-01-31 Janssen Pharmaceutica Nv DIAMINE-PYRIDINE, PYRIMIDINE AND PYRIDAZINE DERIVATIVES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
PE20121352A1 (en) 2009-10-29 2012-10-15 Palau Pharma Sa HETEROARYL DERIVATIVES CONTAINING N AS INHIBITORS OF KINASE JAK3
PE20121505A1 (en) * 2009-12-23 2012-11-05 Medicis Pharmaceutical Corp AMINOALKYLPYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR
CN103857657B (en) 2011-08-18 2016-04-20 日本新药株式会社 Hete rocyclic derivatives and medicine
WO2013182711A1 (en) 2012-06-08 2013-12-12 Sensorion H4 receptor inhibitors for treating tinnitus
WO2014010748A1 (en) * 2012-07-10 2014-01-16 Shionogi & Co., Ltd. Cyclopropane derivative having bace1 inhibiting activity
SG11201507117XA (en) 2013-03-06 2015-10-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
WO2017160922A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US20190083460A1 (en) * 2016-03-16 2019-03-21 Zeno Royalties & Milestones, LLC Analgesic compounds
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
BRPI0615880A2 (en) * 2005-09-13 2011-05-31 Palau Pharma Sa 2-aminopyrimidine-derived compounds as modulators of histamine h4 receptor activity, their use and pharmaceutical composition
NL2000323C2 (en) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (en) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA

Also Published As

Publication number Publication date
TW200936570A (en) 2009-09-01
PE20091035A1 (en) 2009-07-16
AR069480A1 (en) 2010-01-27
WO2009068512A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
CL2008003537A1 (en) 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.
CL2007002018A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION.
CL2008001855A1 (en) Boron-derived condensed cyclic compounds; pharmaceutical composition; and use in the treatment and / or prevention of an infectious disease.
CL2007001992A1 (en) COMPOUNDS DERIVED FROM PYRIMIDILCICLOPENTANOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AN INFLAMMATORY, HYPERPROLIFERANT, CARDIOVASCULAR, NEURODEGE DISEASE
CL2007001870A1 (en) PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE INCLUDING VALSARTAN, AMLODIPINA, HYDROCHLOROTIAZIDA AND PHARMACEUTICALLY ACCEPTABLE ADDITIVES; PREPARATION PROCEDURE; AND USE FOR THE TREATMENT OF HYPERTENSION, CARDIAC INSUFFICIENCY, INFARTO D
CL2008001157A1 (en) Compounds derived from quinoline-carboxamide, antagonists of p2y12; preparation procedure; pharmaceutical composition comprising said compound; composition of a combination of said compounds; and use of the compound in the treatment of cardiovascular disorders, thromboembolism, acute myocardial infarction.
CL2008001373A1 (en) Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
EA201071291A3 (en) NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYATRIC DISORDERS
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
NO20083895L (en) Anti-IGF-1R human monoclonal antibody formulation
BRPI0917315B8 (en) monoclonal antibody, its use and pharmaceutical composition comprising it
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
CR11399A (en) ANTI-BODIES ANTI-IL-12 / 23p40, EPITHOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
CL2008002540A1 (en) Aza-indole-2,3-substituted derivative compounds; pharmaceutical composition; and use in the treatment of a viral infection.
ECSP12011935A (en) TRIAZOLOPIRIDINS
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
CL2008003811A1 (en) 4-aminopyrimidine-2,6-disubstituted derivative compounds, histamine h4 receptor antagonists; Preparation process; pharmaceutical composition comprising said compound; and use of the compound for the treatment of an allergic, immunological or inflammatory disease, or pain.
BRPI1009392A2 (en) "pharmaceutical formulation, and use of a pharmaceutically effective amount of a pharmaceutical formulation."
NI201000189A (en) SOLID MEDICINE FORMULATION WITH DELAYED RELEASE.
UY29459A1 (en) ASTORAPINE MALEATE ORTHROCHEMICAL CRYSTAL FORM AND ITS USE IN THE TREATMENT OF MENTAL DISORDERS
CL2009001137A1 (en) Compounds derived from cycloheptanecarbonyloxy-1-azonia-bicyclo [2.2.2] -octane, modulators of muscarinic receptors; pharmaceutical compositions; process of preparation of said composition; and use in the treatment of chronic obstructive pulmonary disease.
CL2012001757A1 (en) 8-hydroxyquinoline-7-carboxamide derived compounds; pharmaceutical composition; and its use in the treatment of fungal infections.
CL2010000281A1 (en) Oral formulation in tablet form of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline; Preparation method; injectable formulation thereof; Useful in the treatment of an infection.